Neurofilament heavy-chain NfHSMI35 in cerebrospinal fluid supports the differential diagnosis of parkinsonian syndromes
Neurofilament heavy-chain NfHSMI35 in cerebrospinal fluid supports the differential diagnosis of parkinsonian syndromes
复制标题
DOI：
10.1002/mds.21124
复制
发表时间：
2006-12-01
影响因子：
8.6
通讯作者：
Tumani, Hayrettin
中科院分区：
文献类型：
--
作者：
Brettschneider, Johannes;Petzold, Axel;Tumani, Hayrettin
我们的目的是评估脑脊液轴突损伤生物标记物NFH(SMI35)在实验室支持的帕金森综合征鉴别诊断中的潜力。研究对象包括特发性帕金森病(PD；n=22)、多系统萎缩(MSA；n=21)、进行性核上性瘫痪(PSP；n=21)、皮质基底膜变性(CBD；n=6)和年龄匹配的对照组(n=45)。用双抗体夹心法测定脑脊液中NFH(SMI35)水平。PSP组的脑脊液NFH(SMI35)水平高于PD组和对照组(P<；0.05)。MSA组也显著高于PD组和对照组(P<；0.05)。NFH(SMI35)鉴别PD和PSP的敏感性为76.5%，特异性为94.4%。与PD或CBD相比，脑脊液NFH(SMI35)测定的轴突损害在进展较快的PSP和MSA综合征中最为突出。因此，脑脊液NFH(SMI35)可能对实验室支持的非典型帕金森综合征的鉴别诊断有一定的价值。(C)2006年运动无序协会。
We aimed to evaluate the potential of the cerebrospinal fluid (CSF) axonal damage biomarker NfH(SMI35) in the laboratory-supported differential diagnosis of parkinsonian syndromes. Patients with idiopathic Parkinson's disease (PD; n = 22), multiple-system atrophy (MSA; n = 21), progressive supranuclear palsy (PSP; n = 21), corticobasal degeneration (CBD; n = 6), and age-matched controls (n = 45) were included. CSF levels of NfH(SMI35) were measured using ELISA. Levels of CSF NfH(SMI35) were elevated in PSP compared to PD and controls (P < 0.05 each). They were also significantly higher in MSA than in PD and controls (P < 0.05 each). NfH(SMI35) differentiated PD from PSP with a sensitivity of 76.5% and a specificity of 94.4%. Axonal damage as measured by CSF NfH(SMI35) is most prominent in the more rapidly progressive syndromes PSP and MSA as compared to PD or CBD. CSF NfH(SMI35) may therefore be of some value for the laboratory-supported differential diagnosis of atypical parkinsonian syndromes. (C) 2006 Movement Disorder Society.